Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Non-hodgkin's Lymphoma
Interventions
DRUG

Chiauranib

"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."

DRUG

Chidamide

In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY